EBVALLO (tabelecleucel)
EBV+ Post-Transplant Lymphoproliferative Disease (PTLD)
Approved (EU)Commercial
Key Facts
Indication
EBV+ Post-Transplant Lymphoproliferative Disease (PTLD)
Phase
Approved (EU)
Status
Commercial
Company
About Atara Biotherapeutics
Atara Biotherapeutics is a leader in allogeneic T-cell immunotherapy, focused on developing readily available, off-the-shelf cell therapies. Its landmark achievement is the European Commission approval of EBVALLO™ (tabelecleucel) for EBV+ PTLD, the first allogeneic T-cell therapy ever approved. The company's strategy centers on leveraging its proprietary EBV T-cell platform, which avoids gene editing, to build a pipeline targeting cancer and autoimmune diseases, while navigating the complex transition toward commercialization.
View full company profile